Breathe Well Live Well
 GPB |
Glaxo Executives Cited in Case Now Lead Sanofi, Actelion
Businessweek Two senior executives at GlaxoSmithKline Plc (GSK) singled out by the U.S. Justice Department for pushing the Advair asthma drug for unapproved uses have moved on to some of Europe's top pharmaceutical companies. Glaxo Settlement Pulls Back Curtain On Drug Marketing |
View full post on asthma – Google News
|
Actelion ends development of asthma and SAR drug
Pharma Times Actelion has suffered a pipeline setback with the failure of its asthma and seasonal allergic rhinitis drug setipiprant in a mid-stage and a late-stage trial. The Swiss biotech says that it will "re-direct its development efforts in the … |
View full post on asthma – Google News
|
Actelion to end setipiprant clinical development in asthma, allergic rhinitis
RTT News PK: News ) on Monday said two recently concluded studies with the first orally-active CRTH2 antagonist, setipiprant, in asthma and seasonal allergic rhinitis did not confirm efficacy findings made in earlier studies. Accordingly, the company is … Actelion provides update on CRTH2 program |
View full post on asthma – Google News